Search results for "yo"

showing 10 items of 16837 documents

Biodegradable polymer-coated thin strut sirolimus- -eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population.

2021

Background: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular healing. It was sought herein, to determine 1-year clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable coating everolimus-eluting stent (DP-EES). Methods: Patients were retrospectively analyzed with DM were treated with either a BP-SES (ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884)…

medicine.medical_specialtyPercutaneousPolymersmedicine.medical_treatmentPopulation030204 cardiovascular system & hematologyProsthesis DesignCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineAbsorbable ImplantsDiabetes MellitusMedicineHumansMyocardial infarctionEverolimuseducationRetrospective StudiesSirolimuseducation.field_of_studybusiness.industryStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral Medicinemedicine.diseaseInterventional CardiologySurgeryTreatment OutcomeSirolimusConventional PCICardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiology journal
researchProduct

ABSORB everolimus-eluting bioresorbable vascular scaffold systems for the sealing of unstable plaques

2013

Purpose: We set out to investigate the outcome of patients receiving an Absorb bioresorbable vascular scaffold system in the setting of acute coronary syndromes. Background: Everolimus-eluting bioresorbable vascular scaffold systems have recently been introduced in the market for the treatment of coronary artery stenoses. Experience on the use of these devices is limited to type A lesions in elective settings. Treatment of ruptured plaques with bioresorbable scaffold systems might have the advantage to promote the formation of new fibrotic tissue (plaque sealing) without the disadvantages of permanent metal stent implantation. Methods and results: 64 culprit lesions in 63 patients (age 57±1…

medicine.medical_specialtyPercutaneousUnstable anginabusiness.industrymedicine.medical_treatmentStentmedicine.diseaseThrombosisCulpritSurgerymedicine.anatomical_structureInternal medicinemedicineCardiologyCircumflexMyocardial infarctionCardiology and Cardiovascular MedicinebusinessArteryEuropean Heart Journal
researchProduct

Evaluating the quality of implantation of percutaneous ventricular restoration device (Parachute®) by cardiac computed tomography

2016

Background The Parachute is a novel percutaneously implanted ventricular partitioning device (VPD) that has emerged as a safe and feasible treatment option for patients with heart failure following anterior wall myocardial infarction. VPD efficacy is likely dependent on optimal device placement, but to date there are no published data examining the effect of device positioning on patient outcomes. Methods and results We retrospectively identified 32 patients successfully implanted with the Parachute device, all of whom underwent cardiac computed tomography (CCT) at baseline and after 6 months of follow-up. Patients were divided into two groups based on self-reported improvement in New York …

medicine.medical_specialtyPercutaneousbusiness.industrymedicine.medical_treatmentRetrospective cohort studyGeneral MedicineStroke volume030204 cardiovascular system & hematologymedicine.diseaseSurgery03 medical and health sciences0302 clinical medicineHeart failuremedicineRadiology Nuclear Medicine and imagingAnterior Wall Myocardial Infarction030212 general & internal medicineImplantCardiology and Cardiovascular MedicinebusinessVentricular remodelingCardiac catheterizationCatheterization and Cardiovascular Interventions
researchProduct

Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with …

2015

Abstract Background Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4 years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side e…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizin030204 cardiovascular system & hematologyRevascularizationlaw.inventionCohort StudiesCoronary artery disease03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanyAbsorbable ImplantsmedicineHumansEverolimusProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryCoronary StenosisPercutaneous coronary interventionDrug-Eluting StentsGeneral Medicinemedicine.diseaseSurgeryStenosisTreatment OutcomeResearch DesignAustriaCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular Revascularization Medicine
researchProduct

Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-years Results from the GABI-R …

2019

The limitations of the first-generation everolimus-eluting coronary bioresorbable vascular scaffolds (BVS) have been demonstrated in several randomized controlled trials. Little data are available regarding the outcomes of patients receiving hybrid stenting with both BVS and drug-eluting stents (DES). Of 3144 patients prospectively enrolled in the GABI-Registry, 435 (age 62 &plusmn

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizinlcsh:Medicine030204 cardiovascular system & hematologyKoronare HerzkrankheitRevascularizationAbsorbable implantsCoronary artery diseaseArticleCoronary artery diseasedrug eluting stents03 medical and health sciences0302 clinical medicineDrug-eluting StentMedizinische Fakultätstent bioresorbableMedicine030212 general & internal medicineMyocardial infarctionddc:610Drug-eluting stentsTissue scaffoldsEverolimusbusiness.industrylcsh:RStentGeneral Medicinemedicine.diseaseThrombosisSurgeryConventional PCIbusinessDDC 610 / Medicine & healthcoronary artery diseasemedicine.drugJournal of Clinical Medicine
researchProduct

Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-…

2019

Abstract Aims ST-segment elevation myocardial infarction (STEMI) guidelines recommend primary percutaneous coronary intervention (pPCI) as the default reperfusion strategy when feasible ≤120 min of diagnostic ECG, and a pharmaco-invasive strategy otherwise. There is, however, a lack of direct evidence to support the guidelines, and in real-world situations, pPCI is often performed beyond recommended timelines. To assess 5-year outcomes according to timing of pPCI (timely vs. late) compared with a pharmaco-invasive strategy (fibrinolysis with referral to PCI centre). Methods and results The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme c…

medicine.medical_specialtyPercutaneousmedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionAcute myocardial infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic Agents[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFibrinolysismedicineHumansST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesTimingPrimary PCIbusiness.industryFibrinolysisHazard ratioPercutaneous coronary interventionmedicine.diseaseLong-term outcome3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV] Life Sciences [q-bio]Treatment OutcomeEmergency medicineConventional PCIST Elevation Myocardial InfarctionCardiology and Cardiovascular Medicinebusiness
researchProduct

Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all

2020

: Periodontal disease is conventionally defined as an inflammatory condition affecting the tissues surrounding and supporting the teeth (i.e. gum and periodontium). Recent statistics show that the prevalence of this condition is continuously growing worldwide, thus raising severe healthcare concerns, not only for local problems emerging from poor oral health, but also for the potential risk of developing systemic complications. Therefore, this article aims to provide an update on the intriguing association between periodontitis, coronary heart disease (CHD) and/or myocardial infarction (MI). Taken together, the available published information seems to support the existence of a significant …

medicine.medical_specialtyPeriodontitis coronary heart disease myocardial infarctionCoronary Artery Disease030204 cardiovascular system & hematologyOverweightCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineAnimalsHumansMyocardial infarctionEndothelial dysfunctioncoronary heart diseasePeriodontitisPeriodontitisbusiness.industryHematologyGeneral MedicinePeriodontiummedicine.diseaseCoronary heart diseaseTreatment Outcomemyocardial infarctionmedicine.symptomHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness030215 immunology
researchProduct

Calcium Dependence of the Mechanical Response Evoked by Okadaic Acid in Smooth Muscle

1995

The effects of okadaic acid (OA), obtained from a culture of the marine dinoflagellate Prorocentrum Lima were studied on isolated strips of rat myometrium. The contractile response evoked by OA at 5, 10, and 20 μM in normal physiological solution was unaffected in the presence of tetrodotoxin (10 μM), indomethacin (3 μM), or a cocktail of antagonists which blocked muscarinic, adrenergic, histaminergic, serotonergic, and opioid receptors. Similarly, the response to OA was unaffected in the presence of nifedipine at a concentration (1 μM) which completely or highly blocked the response to KCl (60 mM), oxytocin (1 μM), or acetylcholine (100 μM). In a Ca 2+ -free 1 mM EGTA-containing solution, …

medicine.medical_specialtyPharmaceutical Sciencechemistry.chemical_elementIn Vitro TechniquesCalciumBiologyAnalytical ChemistryRats Sprague-Dawleychemistry.chemical_compoundEthers CyclicInternal medicineOkadaic AcidDrug DiscoveryMuscarinic acetylcholine receptormedicineAnimalsVanadatePharmacologyOrganic ChemistryMyometriumOkadaic acidRatsEGTAEndocrinologyComplementary and alternative medicinechemistryMyometriumMolecular MedicineCalciumFemalemedicine.symptomAcetylcholineMuscle ContractionMuscle contractionmedicine.drugPlanta Medica
researchProduct

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregna…

2021

Abstract Myeloproliferative neoplasms (MPN) are traditionally regarded as a disease of older adults, though a not negligible fraction of cases occurs at a younger age, including women of childbearing potential. MPN in younger patients, indeed, offer several challenges for the clinical hematologist, that goes from difficulties in reaching a timely and accurate diagnosis to a peculiar thrombotic risk, with a relatively high incidence of thromboses in unusual sites (as the splanchnic veins or the cerebral ones). Moreover, the issue of pregnancy is recently gaining more attention as maternal age is rising and molecular screening are widely implemented, leading to a better recognition of these c…

medicine.medical_specialtyPhiladelphia Chromosome NegativeMyeloproliferative neoplasmDiseaseEssential thrombocythemiaCritical discussionMyeloproliferative neoplasmsAntiphospholipid syndromePregnancyNeoplasmsmedicineHumansPhiladelphia ChromosomeHematologistIntensive care medicineAgedEssential thrombocythemia; Myeloproliferative neoplasms; PregnancyPregnancyMyeloproliferative DisordersEssential thrombocythemiabusiness.industryIncidencefood and beveragesThrombosisHematologymedicine.diseaseOncologyYounger adultsFemalebusinessmanagement
researchProduct

Morphometry of myocardial apex in endurance-trained mice of different ages

1979

Mitochondrial volume density, surface density of the outer mitochondrial membrane, the mean number and size of mitochondria, and the mean surface density of crista membranes together with the volume densities of myofibrils and sarcoplasmic space were morpho-metrically analyzed in cardiac muscle of two groups of sedentary control mice aged 3 and 7 months, and in two groups of mice trained either 1 month rather intensely or 4 months moderately. Of the calculated mitochondrial variables only the surface density of the outer mitochondrial membrane differed between the older controls and the older trained animals, the density being slightly smaller in the trained group. The myofibrillar volume d…

medicine.medical_specialtyPhysical Education and TrainingTime FactorsPhysiologyMyocardiumSarcoplasmAge FactorsCardiac muscleStereologyOrgan SizeBiologyMitochondria HeartMiceCristamedicine.anatomical_structureCardiac muscle hypertrophyEndocrinologyEndurance trainingInternal medicinePhysical EndurancemedicineAnimalsMyocyteMyofibrilActa Physiologica Scandinavica
researchProduct